# Ultragenyx plans staff cuts and ends Wilson disease gene therapy development

_Published Thursday, November 5, 2026 at 9:18 PM EST · Science · Latest · Tier 2 — Notable_

![Ultragenyx plans staff cuts and ends Wilson disease gene therapy development — Primary](https://cdn.thepharmaletter.com/convert/files/2024/06/4e5bab90-21c1-11ef-b9fd-3d6df514ffbd-logo-ultragenyx-copro.png/r%5Bwidth%5D=1280/4e5bab90-21c1-11ef-b9fd-3d6df514ffbd-logo-ultragenyx-copro.png)

Ultragenyx plans to cut headcount by about 20%, to roughly 1,000 employees, and terminate development of UX701, its gene therapy for Wilson disease, The Pharma Letter reported.

The rare disease drugmaker is shifting toward commercial execution and a smaller research footprint after two gene therapy approvals. It is also completing the wind-down of all ongoing GTX-102 studies for Angelman syndrome and reducing costs, including real estate.

## Sources

- [The Pharma Letter](https://www.thepharmaletter.com/biotech-news/ultragenyx-cuts-20-of-staff-and-ends-wilson-disease-gene-therapy-as-it-targets-2027-profitability)

---
Canonical: https://techandbusiness.org/newswire/GE74zfz1ARrEvuUofRWeLZ
Published: 2026-11-06T02:18:42.118Z
Story chronology: 2026-11-05T12:41:51.609Z
Retrieved: 2026-11-06T23:12:45.209Z
Publisher: Tech & Business (techandbusiness.org)